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Abstract 
New structurally simple indolic non peptidic HIV Protease inhibitors were synthesized from (S)-
glycidol by regioselective methods. Following the concept of targeting the protein backbone, 
different substitution patterns were introduced onto the common stereodefined 
isopropanolamine core modifying the type of functional group on the indole, the position of the 
functional group on the indole and the type of the nitrogen containing group (sulfonamides or 
perhydroisoquinoline), alternatively. The systematic study on in vitro inhibition activity of such 
compounds confirmed the general beneficial effect of the 5-indolyl substituents in presence of 
arylsulfonamide moieties, which furnished activities in the micromolar range. Preliminary docking 
analysis allowed to identify several key features of the binding mode of such compounds to the 
protease. 
 
  
Introduction 
The devastating effect of the AIDS epidemic is still a reality. However, since the highly active 
antiretroviral therapy (HAART) has been employed to combat the illness, HIV infection has 
definitely become more manageable.
1
 During the last 20 years an unprecedented success has 
been achieved in discovering anti-HIV drugs as reflected by the fact that there are now more drugs 
approved for the treatment of HIV than for all other viral infections taken together. 
The currently FDA approved anti-HIV drugs can be divided into seven groups: nucleoside reverse 
transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, non-nucleoside reverse 
transcriptase inhibitors, protease inhibitors (PIs), fusion inhibitors, co-receptor inhibitors, and 
integrase inhibitors.2 Detailed knowledge of the structure of HIV protease and its substrate has led 
to the preparation of specific PIs, whose arrival was a pivotal moment in the development of 
antiretroviral therapy and made possible the dual class triple combination therapy.3 Despite the 
already marketed PIs have an evident crucial role into HAART regimen, their clinical utility can be 
limited by low bioavailability and reduced long-term viral inhibition, with multiple protease 
resistance mutations being observed. Thus, novel PIs with high potency against the known HIV 
protease variants have been designed. We recently demonstrated the beneficial effect of a 
heteroaromatic group in a series of new thienyl ring containing analogues of nelfinavir and 
saquinavir, which showed to maintain or even increase their activity against either wild type or 
mutant HIV protease.
4
 Recently the concept of targeting the protein backbone in structure-based 
drug design was introduced. Thus new non-peptidic templates, which can maximize interactions in 
the HIV-protease active site, particularly with the enzyme backbone atoms, were developed.
5
 Both 
extensive hydrogen bonding and hydrophobic interactions with enzyme subsites can limit the 
protease ability to acquire drug resistance as the geometry of the catalytic site must be conserved 
to maintain functionality.6 This new concept allowed to design different compounds of very simple 
structure and to focus the interest more toward their easy synthetic availability and less to 
structural similarity. Our preliminary investigation showed the beneficial effect of indolyl ring on a 
simple substituted stereodefined isopropanolamine core.
7
 In this respect, with the aim of finding 
new easily accessible non-peptidic PIs, we started a systematic study on the synthesis and 
inhibition activity of new indolyl derivatives with general structure A (Fig. 1), modifying the 
following parameters: 
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Figure 1 
1) type of functional group on the indole 
2) position of the functional group on the indole 
3) type of the nitrogen containing group R
1
 and R
2
 (sulfonamides or PHIQ) 
 
Results and discussion 
Although the synthetic work can appear tedious at a first sight, we took advantage of the 
commercially available bidentate electrophile (S)-glycidol 1 for the generation of the core (scheme 
1). The glycidol was first activated by the reaction with m-nosyl chloride to obtain compound 2. 
The subsequent nucleophilic displacement of the nosyl group was performed by the commercially 
available 4-, 5-, or 6-hydroxyindoles affording the corresponding oxyindoles 3, 4 and 5 in good 
yields and mild reaction conditions, without any competitive epoxide ring opening.
8
 Each 
oxyindole represents the common precursor for the preparation of either perhydroisoquinyl- or 
sulfonamidyl derivatives. Indeed, perhydroisoquinoline (PHIQ) was introduced by direct 
regioselective oxiranyl ring opening, obtaining the corresponding 6, 7 and 8 in good yield and as 
single diastereoisomers (> 57% overall yield in 3 steps). 
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Scheme 1 
 
For the preparation of arylsulfonamidyl compounds, the oxiranyl-oxyindoles 3, 4 and 5 were 
reacted with isobutylamine, affording the amino-derivatives 9, 10 and 11 in excellent yield. 
Starting from this triad, arylsulfonyl fragments with different electronic properties were 
introduced by employing suitable chlorides, affording compounds 12a,b, 13a,b and 14a,b (> 46% 
overall yield in 4 steps). In particular, electron releasing 3,4-dimethoxyphenyl- and electron 
withdrawing 4-nitrophenyl groups were introduced to evaluate their potentially different effect on 
inhibitory activity. Compound 13a was also transformed into 4-aminophenyl derivative 13c by Pd-
catalyzed hydrogenation. 
  
All these oxyindoles were tested in vitro for anti HIV-PR activity and the results are reported in 
Table 1. 
Table 1. 
Regioisomer PHIQ (IC50, µM) 4-NO2C6H4SO2NR  
(4-NH2C6H4SO2NR) 
(IC50, µM) 
3,4-diMeOC6H4SO2NR 
(IC50, µM) 
HN
O N
R1
R2
OH
 
4-oxyindole 
6 (24) 12a (346) 12b (336) 
O
N
H
N
R1
R2
OH
 
5-oxyindole 
7 (14) 13a (10) 
(13c (12)) 
13b (1) 
NH
O
OH
N
R1
R2
 
6-oxyindole 
8 (138) 14a (46) 14b (346) 
IC50 values were obtained by measuring the initial rates of hydrolysis of the fluorogenic substrate Abz-Thr-Ile-Nle-
Phe(NO2)-Gln-Arg. Results are the mean of at least three independent experiments. 
 
This systematic study confirms the trend observed in our preliminary results on oxyindoles.7b In 
general 5-oxyindoles show better activity than the 4- and 6-substituted ones and this difference is 
highly amplified by the presence of sulfonamidyl groups, no matter which substituent is placed on 
the aryl ring. Promising IC50 value of 1.04 µM was obtained for compound 13b, suggesting a 
beneficial effect of the two methoxy groups on the aryl ring. This is in line with the reported data 
for derivatives of Darunavir in which the aniline group is replaced by 1,3-dioxolane group.
9
 The 
two oxygen atoms are thought to interact with the protease by two direct hydrogen bonds and a 
water-mediated interaction with Gly 48, which may stabilize the flexible flap region. 
Next step of our study was to change the functionality on the indole ring, so we focused our 
attention on amino indoles. PHIQ derivatives 15 and 16 were recently prepared starting from 
available 4- and 5-aminoindoles and (S)-glycidol, by a slight modification of our synthetic approach 
(figure 2).
7b
 Their potency was disappointing, the IC50 values ranging between 150 and 180 µM. 
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Thus, we wanted to prepare and test the corresponding 4-nitro- and 3,4-dimethoxyphenyl-
sulphonamidyl derivatives. (S)-glycidol was regioselectively opened with i-BuNH2, affording the 
aminodiol 17 (scheme 2). 
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Scheme 2 
 
Then the suitable arylsulfonyl moiety was introduced, namely 4-nitro- and 3,4-
dimethoxyphenylsulfonyl groups, in high yield giving 18a and 18b. After regioselective tosylation 
of primary hydroxyl group, the two epoxides 19a and 19b were alternatively prepared, and they 
were finally opened with 4- and 5-aminoindoles, affording the four new derivatives 22a,b and 
23a,b (> 41% overall yield in 5 steps). In vitro tests of these aminoindolyl compounds against wild 
type HIV-1 PR are reported in Table 2. 
 
 
 
 
  
Table 2 
Regioisomer 4-NO2C6H4SO2NR 
(IC50, µM) 
3,4-diMeOC6H4SO2NR 
(IC50, µM) 
HN
H
N N
R1
R2
OH
 
4-aminoindole 
22a (2630) 22b (336) 
H
N
N
H
N
R1
R2
OH
 
5-aminoindole 
23a (inactive) 23b (4400) 
 
These results pointed out the general negative effect of amino group on the inhibition activity of 
indole derivatives, whatever the position of the nitrogen on the heterocycle. The introduction of 
sulfonamidyl groups instead of PHIQ even reduced the activity of the resulting compounds. 
Finally, we wanted to investigate the effect of carbamoyl moiety, instead of amino group, 
considering its beneficial effect in certain non peptidic inhibitors, as Darunavir.10 
The preparation of the corresponding carbamoyl derivatives of 4- and 5-indoles was 
straightforward. 4- and 5-aminoindoles 20 and 21 were first reacted with p-
nitrophenylchlorocarbonate, to afford the activated carbamates 24 and 25 (scheme 3). Glycidol 
was then introduced by substitution reaction, and the common intermediates oxiranyl carbamates 
26 and 27 were obtained in good yield. 
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Scheme 3 
 
These intermediates were alternatively transformed into PHIQ derivatives 28, 29 (> 67% overall 
yield in 3 steps) and sulfonamides 32a,b, 33a,b,c (> 63% overall yield in 4 steps) by oxiranyl ring 
opening with PHIQ and iso-butylamine followed by sulfonylation, respectively. 
All these carbamates were tested and their inhibition activities are listed in Table 3. 
Table 3 
Regioisomer PHIQ 
(IC50, µM) 
4-NO2C6H4SO2NR 
(IC50, µM) 
3,4-diMeOC6H4SO2NR 
(IC50, µM) 
H
N
N
H
N
R1
R2
OH
 
4-carbamoyl 
28 (50) 32a (72) 32b (615) 
H
N
N
H
O N
R1
R2
OH
O
 
5-carbamoyl 
29 (606) 33a (2) 33b (1400) 
33c (4-OMe) (8) 
 
  
Although the general positive effect on the activity of the substitution of amino group with 
carbamoyl one, usually ranging in the micromolar values, the results appear difficult to rationalize. 
PHIQ moiety contributes better on 4-indole derivative, whether arylsulphonamide group matches 
with 5-indole one. Such a structure is very sensitive to the overall length of the molecule, 
depending on the linkage between the indole ring and the core of the inhibitor, and requires a 
careful selection of the substituents on the aryl system. Thus, the 3,4-dimethoxy aryl system is 
favourable in compounds as 13b, but fails entirely in the corresponding carbamate 33b, with an 
extremely high IC50 of 1.4 mM. Conversely, the nitroaryl system is effective in both the series of 
inhibitors. To address this point, we have carried out a preliminary computational analysis by 
docking inhibitors 13, 23 and 33 inside the proteases. Analysis of the docked poses shows that the 
activities of the inhibitors are determined by the distance between the hydrophobic part of the 
indole ring and the central carbon atom. For one atom linkers, -O- or -N-, the indole ring lies 
mostly in sub-site S1, rather than in sub-site S2. For a longer linker as the carbamate one, the 
indole ring will lie in S2 but this forces the arylsulphonamide side of the molecules to a deeper 
extent inside S2’ subsite (Figure 3). 
  
 
 
Figure 3
11
. Binding poses of some active compounds; HIV PR were presented with red/green 
ribbons or sticks. Darunavir was used as the reference and is presented as yellow sticks. Ligands 
are shown as ball and sticks, coloured by atom types. a) crystal structure of darunavir with HIV PR. 
b) binding mode of 13b. c) binding mode of 33b. d) binding mode of 33c. 
  
The nitro- (13a) or one of the two methoxy- groups (13b, Figure 3b) could establish favourable 
hydrogen bonding with the backbone amide proton of Asp30’. However, the second methoxy- 
group in the larger 33b structure, clearly leads to unfavourable steric clash (Figure 3c). This 
prompted us to remove such a group as in 33c (Figure 3c), and this led to a three orders of 
magnitude gain in activity (see Table 3). 
Conclusion 
In conclusion, our systematic study confirmed the possibility of introducing indole ring in anti-HIV-
1 PR inhibitors which are active in the micromolar range. Although the net contribution of the 
individual substituents cannot be fully rationalized, the following general insights may be found: 
a) oxyindoles and carbamoyl indoles showed general good activity, whereas simple aminoindoles 
are much less active, 
b) 5-substituted indoles appear to be the best regioisomers, apparently they fit better into the S1 
or S2 site of the enzyme, depending on the linker length and distance from the core, 
c) arylsulfonamidyl moieties are in general beneficial for the inhibition activity, but their effect is 
compound type-dependent: 5-oxyindole matches with 3,4-diOMe-phenylsulfonamide group at 
best, whilst 5-carbamoyl indole matches well with both 4-NO2- and 4-OMe-phenylsulfonamide 
moiety, with a slight preference for the former, 
d) a preliminary docking analysis allowed to identify several key features of the binding mode of 
our compounds to the protease, prompting further developments of inhibitors with improved 
activity. 
 
Experimental section 
Chemistry 
Preparative chromatography was carried out on Merck silica gel (0.063–0.200 mm particle size) by 
progressive elution with opportune solvent mixtures. 1H and 13C NMR spectra were normally 
carried out in CDCl3 solutions on a VARIAN INOVA 500 MHz or Bruker 400 MHz and referenced to 
Me4Si. Mass spectra were obtained with a Hewlett–Packard 5971 mass-selective detector on a 
Hewlett–Packard 5890 gas chromatograph [(OV-1 capillary column between 70 and 250 °C (20 °C 
min-1)]. The optical purity was evaluated by using a polarimeter JASCO Mod Dip-370. 
Dichloromethane was dried by distillation over anhydrous CaCl2 in inert atmosphere. Dry 
dimethylformamide was commercially available. Compound 2 was prepared according to the 
literature
8a, 12
 starting from the commercially available (S)-(-)-glycidol 1. 
  
 
Nosyl displacement with hydroxyindoles: general procedure 
K2CO3 (0.1433 g, 1.04 mmol) was added to a stirred solution of hydroxyindole (0.0461 g, 0.35 
mmol) in dry DMF (4 mL) at room temperature under argon atmosphere; after 1 h a DMF solution 
(3 mL) of compound 2 (0.0815 g, 0.31 mmol) was added and the mixture was stirred overnight. 
After 14 h (TLC control, CHCl3/ CH3OH 99:1) the reaction mixture was quenched by adding 
ammonium chloride (saturated aqueous solution), then was extracted with diethyl ether and the 
organic layer washed with brine. After drying over Na2SO4, the organic layer was concentrated in 
vacuo and the crude was purified by column chromatography on silica gel (eluent: CH2Cl2/EtOAc 
99:1) 
(-)-(R)-4-Oxiranylmethoxy-1H-indole (3) 
Compound 3 was isolated as a brown thick oil (0.038 g, 63%). [α]D
20
 -6.4 (c 1.6, CHCl3); Rf 0.5 
(CH2Cl2/EtOAc 99:1); δH (500 MHz, CDCl3) 8.25 (1H, s), 7.14–7.05 (3H, m), 6.71 (1H, t, J = 2.5 Hz), 
6.55 (1H, d, J = 8.0 Hz), 4.38 (1H, dd, J = 3.0 and 11.0 Hz), 4.17 (1H, dd, J = 6.0 and 11.0 Hz), 3.49– 
3.47 (1H, m), 2.96 (1H, t, J = 5.0 Hz), 2.85 (1H, dd, J = 2.5 and 5.0 Hz); δC (125 MHz, CDCl3) 152.1, 
133.2, 127.1, 120.5, 117.6, 112.3, 103.4, 102.7, 70.5, 50.9, 44.3. MS (EI)m/z: 189 (M
+
) (100), 132 
(63), 104 (50). Anal. Calcd for C11H11NO2: C, 69.83; H, 5.86; N, 7.40. Found: C, 69.85; H, 5.84; N, 
7.45. 
(-)-(R)-5-Oxiranylmethoxy-1H-indole (4) 
Compound 4 was isolated as a brown thick oil (0.045 g, 72%). [α]D
20
 -2.2 (c 1.2, CHCl3); Rf 0.5 
(CH2Cl2/EtOAc 99:1); δH (500 MHz, CDCl3) 8.16 (1H, s), 7.31–7.14 (3H, m), 6.92 (1H, dd, J = 1.5 and 
8.5 Hz), 6.5 (1H, s), 4.27 (1H, dd, J = 3.5 and 12.0 Hz), 4.04 (1H, dd, J = 6 and 11.0 Hz), 3.43–3.42 
(1H, m), 2.94 (1H, t, J = 4.5 Hz), 2.81 (1H, dd, J 3.0 and 5.5 Hz); δC (125 MHz, CDCl3) 153.0, 131.2, 
128.1, 125.0, 112.8, 111.7, 103.8, 102.3, 69.6, 50.4, 44.9; MS (EI) m/z: 189 (M+) (100), 132 (80), 
104 (54). Anal. Calcd for C11H11NO2: C, 69.83; H, 5.86, N, 7.40. Found: C, 69.82; H, 5.87; N, 7.35. 
(-)-(R)-6-Oxiranylmethoxy-1H-indole (5) 
Compound 5 was isolated as a yellow solid (0.036 g, 61%). Mp 105 °C; [α]D
20
 -3.4 (c 1, CHCl3); Rf 
0.4 (CH2Cl2/EtOAc 99:1); δH (500 MHz, CDCl3) 8.15 (1H, s), 7.54 (1H, d, J = 11.0 Hz), 7.09 (1H, s), 
6.85 (2H, d, J = 6.5 Hz), 6.50 (1H, d, J = 1.0 Hz), 4.24 (1H, dd, J = 1.5 and 13.5 Hz), 3.96 (1H, dd, J = 
7.0 and 14.0 Hz), 3.39 (1H, m), 2.93–2.78 (2H, m); δC (125 MHz, CDCl3) 155.1, 136.3, 123.4, 122.5, 
121.2, 110.2, 102.2, 95.9, 69.3, 50.3, 44.7; MS (EI) m/z: 189 (M+) (100), 132 (80), 104 (54). Anal. 
Calcd for C11H11NO2: C, 69.83; H, 5.86; N, 7.40. Found: C, 69.82; H, 5.87; N, 7.38. 
  
 
Ring opening of the epoxides with PHIQ: general procedure 
PHIQ (0.043 g, 0.18 mmol) was added to a stirred solution of suitable epoxide (0.15 mmol) in i-
PrOH (2 mL) at room temperature. After 20 h the solvent was removed under reduced pressure 
and the crude purified by column chromatography on silica gel (CHCl3/CH3OH 95:5). 
 
(-)-(3S,4aS,8aS)-2-[(2R)-Hydroxy-3-(1H-indol-4-yloxy)-propyl]-decahydro-isoquinoline-3-carboxylic 
acid tert-butylamide (6) 
Compound 6 was isolated as a pink solid (0.061 g, 91%); mp 85 °C; [α]D
20 -61.2 (c 1.5, CHCl3); Rf 0.4 
(CHCl3/CH3OH 95:5); δH (500 MHz, CDCl3) 8.51 (1H, s), 7.14–7.06 (3H, m), 6.65 (1H, d, J = 2.5 Hz), 
6.53 (1H, d, J = 7.5 Hz), 6.25 (1H, s, NH), 4.42 (1H, d, J = 9.0 Hz), 4.07 (1H, t, J = 8.0 Hz), 3.12 (1H, s, 
OH), 2.99 (1H, d, J = 7.5 Hz), 2.78 (1H, d, J = 8.0 Hz), 2.66 (1H, d, J = 8.0 Hz), 2.44 (1H, d, J = 7.5 Hz), 
2.31 (1H, d, J = 8.0 Hz), 1.92–1.39 (9H, m), 1.34 (9H, s), 1.28–1.16 (4H, m); δC (125 MHz, CDCl3) 
171.5, 152.1, 137.3, 122.8, 122.5, 118.6, 105.1, 100.7, 99.5, 70.4, 68.2, 59.5, 58.4, 50.6, 35.7, 33.1, 
30.8, 30.6, 28.6, 26.1, 25.7, 20.4. IR (cm-1) 3311, 2925, 1652, 1365. Anal. Calcd for C25H37N3O3: C, 
70.22; H, 8.72; N, 9.83. Found: C, 70.20; H, 8.73; N, 9.80. 
 
(-)-(3S,4aS,8aS)-2-[(2R)-Hydroxy-3-(1H-indol-5-yloxy)-propyl]-decahydro-isoquinoline-3-carboxylic 
acid tert-butylamide (7) 
Compound 7 was isolated as a yellow thick oil (0.063 g, 87%); [α]D
20
 -70.3 (c 2, CHCl3); Rf 0.4 
(CHCl3/CH3OH 95:5); δH (500 MHz, CDCl3) 8.45 (1H, s), 7.29 (1H, t, J = 9.0 Hz), 7.21 (1H, t, J = 2.5 
Hz), 7.11 (1H, d, J = 2.5 Hz), 6.87 (1H, dd, J = 2.5 and 9.0 Hz), 6.47 (1H, t, J = 2.5 Hz), 6.29 (1H, s, 
NH), 4.19 (1H, s,OH), 4.11 (1H, dd, J = 4.0 and 9.5 Hz), 3.95 (1H, dd, J = 7.0 and 9.0 Hz), 3.01–2.22 
(5H, m), 1.91–139 (10H, m), 1.35 (9H, s), 1.22–1.18 (3H, m); δC (125 MHz, CDCl3) 173.9, 152.9, 
131.3, 128.2, 125.1, 112.6, 111.8, 103.7, 102.7, 71.2, 70.3, 68.3, 59.4, 58.6, 50.7, 35.7, 35.7, 33.1, 
30.8, 30.6, 29.6, 28.6, 26.1, 25.7, 20.5. IR (cm-1) 3311, 2925, 1652, 1365. Anal. Calcd for 
C25H37N3O3: C, 70.22; H, 8.72; N, 9.83. Found: C, 70.19; H, 8.76; N, 9.85. 
 
(-)-(3S,4aS,8aS)-2-[(2R)-Hydroxy-3-(1H-indol-6-yloxy)-propyl]-decahydro-isoquinoline-3-carboxylic 
acid tert-butylamide (8) 
Compound 8 was isolated as a brown thick oil (0.063 g, 93%); [α]D
20
 -66.0 (c 1.3, CH3OH); Rf 0.6 
(CHCl3/CH3OH 95:5); δH (500 MHz, CDCl3) 8.53 (1H, s), 7.51 (1H, d, J = 8.5 Hz), 7.21 (1H, t, J = 2.5 
  
Hz), 6.90 (1H, d, J = 2.0 Hz), 6.79 (1H, dd, J = 2.5 and 9.0 Hz), 6.48 (1H, t, J = 2.0 Hz), 6.24 (1H, s, 
NH), 4.16 (1H, t, J = 5.0 Hz), 4.08 (1H, dd, J = 4.5 and 9.0 Hz), 3.95 (1H, dd, J 6.5 and 9.5 Hz), 2.95 
(1H, dd, J = 2.0 and 11.5 Hz), 2.76–2.64 (2H, m), 2.4 (1H, dd, J = 5.0 and 13.5 Hz), 2.28 (1H, dd, J = 
3.0 and 12.0 Hz), 1.92–1.40 (11H, m), 1.37 (9H, s), 1.34–1.21 (3H, m); δC (125 MHz, CDCl3) 174.0, 
155.0, 136.4, 123.4, 122.5, 121.1, 110.1, 102.1, 95.9, 70.9, 70.2, 68.3, 59.5, 58.5, 50.7, 35.7, 33.1, 
30.8, 30.6, 28.6, 26.1, 25.7, 20.5. IR (cm
-1
) 3311, 2925, 1652, 1365. Anal. Calcd for C25H37N3O3: C, 
70.22; H, 8.72; N, 9.83. Found: C, 70.20; H, 8.71; N, 9.86. 
(-)-(3S,4aS,8aS)-(1H-Indol-4-yl)-carbamic acid 3-(3-tert-butylcarbamoyl-octahydro-isoquinolin-2-yl)-
(2R)-hydroxy-propyl ester (28) 
Compound 28 was isolated as a brown powder (0.050 g, 80%) starting from 27. Mp 130 °C; [α]D
20
 
+36.0 (c 1, CH3OH); Rf 0.8 (CHCl3/CH3OH 9:1); δH (500 MHz, CDCl3) 8.68 (1H, s), 7.11 (1H, t, J =2.5 
Hz), 6.85 (1H, d, J 8.0 Hz), 6.48–6.35 (3H, m), 4.37 (1H, d, J = 8.0 Hz), 4.06–4.11 (2H, m), 2.90 (1H, 
d, J = 11.5 Hz), 2.65 (1H, t, J = 5.0 Hz), 2.26 (2H, t, J = 12.0 Hz), 2.23–1.38 (11H, m), 1.36 (9H, s), 
1.21–1.18 (3H, m); δC (125 MHz, CDCl3) 173.7, 138.6, 136.7, 129.7, 128.1, 125.2, 115.7, 111.3, 
106.4, 102.6, 70.1, 68.1, 59.4, 58.8, 55.7, 50.8, 35.7, 33.0, 31.9, 30.7, 30.6, 29.7, 29.3, 25.7. IR (cm
-
1) 3411, 3282, 3042, 2937, 1731, 1642, 1312, 1238, 1124. Anal. Calcd for C26H38N4O4: C, 66.36; H, 
8.14; N, 11.91 Found: C, 66.33; H, 8.18; N, 11.88. 
(-)-(3S,4aS,8aS)-(1H-Indol-5-yl)-carbamic acid 3-(3-tert-butylcarbamoyl-octahydro-isoquinolin-2-yl)-
(2R)-hydroxy-propyl ester (29) 
Compound 29 was isolated as a brown powder (0.052 g, 75%) starting from 27. Mp 139 °C; [α]D
20 
+42.0 (c 1.2, CH3OH); Rf 0.6 (CHCl3/CH3OH 9:1); δH (500 MHz, CDCl3) 8.31 (1H, s), 7.68 (1H, s), 7.31 
(1H, d, J = 9.0 Hz), 7.21 (1H, t, J = 2.5 Hz), 7.11 (1H, d, J = 8.0 Hz), 6.85 (1H, br s), 6.47 (1H, t, J = 2.5 
Hz), 6.50 (1H, s), 6.16 (1H, s), 4.39 (1H, d, J = 8.0 Hz), 4.08–4.12 (2H, m), 2.92 (1H, d, J = 11.5 Hz), 
2.63 (1H, t, J = 5.0 Hz), 2.28 (2H, t, J = 12.0 Hz), 2.22–1.39 (11H, m), 1.35 (9H, s), 1.22–1.18 (3H, m); 
δC (125 MHz, CDCl3) 173.7, 154.4, 133.1, 130.0, 129.7, 128.1, 125.2, 115.7, 111.3, 102.6, 70.1, 68.1, 
59.4, 58.8, 50.8, 35.7, 33.0, 31.9, 30.7, 30.6, 29.7, 29.3, 28.7, 26.1, 25.7, 20.6. IR (cm
-1
) 3410, 3280, 
3046, 2939, 1730, 1642, 1308, 1245, 1128. Anal. Calcd for C26H38N4O4: C, 66.36; H, 8.14; N, 11.91. 
Found: C, 66.39; H, 7.15; N, 11.93. 
 
Ring opening of the epoxides with iso-butylamine: general procedure 
i-ButNH2 (1.12 g, 1.48 mmol) was added to a stirred solution of suitable epoxide (1.38 mmol) in i-
PrOH (30 mL) at room temperature for 26 h. Then the solvent was removed under reduced 
  
pressure. The crudes of compounds 11, 17 and 30 were used in the subsequent reaction without 
any purification. Compounds 9, 10 and 31 were purified by column chromatography on silica gel. 
 
(+)-(R)-1-(1H-Indol-4-yloxy)-3-isobutylamino-propan-2-ol (9) 
Compound 9 was obtained as a colourless thick oil (0.400 g, 99%). [α]D
20 +6.8 (c 1.2, CHCl3); Rf 0.5 
(CHCl3/CH3OH 9:1); δH (500 MHz, CDCl3) 8.30 (1H, s), 7.14–7.05 (3H, m), 6.68 (1H, d, J = 2.5 Hz), 
6.55 (1H, d, J= 7.5 Hz), 4.20–4.15 (1H, m), 2.95–2.85 (2H, m), 3.72–3.68 (2H, m), 2.87 (2H, d, J = 7.0 
Hz), 1.85–1.80 (1H, m), 0.94 (3H, d, J = 3.5 Hz), 0.93 (3H, d, J = 3.5 Hz); δC (125 MHz, CDCl3) 152.9, 
131.2, 128.2, 125.1, 112.4, 111.7, 103.6, 101.9, 71.3, 67.9, 57.4, 51.8, 27.7, 20.4. IR (cm
-1
) 3402, 
3313, 3050, 2958, 1455, 1159. Anal. Calcd for C15H22N2O2: C, 68.67; H, 8.45; N, 10.68. Found: C, 
68.69; H, 8.43; N, 10.72. 
(+)-(R)-1-(1H-Indol-5-yloxy)-3-isobutylamino-propan-2-ol (10) 
Compound 10 was obtained as a colourless thick oil (0.358 g, 99%). [α]D
20
 +6.5 (c 1.3, CH3OH); Rf 
0.5 (CHCl3/CH3OH 9:1); δH (500 MHz, CDCl3) 8.66 (1H, s), 7.25–7.10 (3H, m), 6.85 (1H, dd, J = 1.5 
and 8.5 Hz), 6.45 (1H, s), 4.22–4.18 (1H, m), 4.02–3.97 (2H, m), 3.72–3.68 (2H, m), 2.87 (2H, d, J = 
7.0 Hz), 1.85–1.80 (1H, m), 0.94 (3H, d, J = 3.5 Hz), 0.93 (3H, d, J = 3.5 Hz); δC (125 MHz, CDCl3) 
152.9, 131.2, 128.2, 125.1, 112.4, 111.7, 103.6, 101.9, 71.3, 67.9, 57.4, 51.8, 27.7, 20.4. IR (cm
-1
) 
3402, 3313, 3050, 2958, 1455, 1159. Anal. Calcd for C15H22N2O2: C, 68.67; H, 8.45; N, 10.68. Found: 
C, 68.69; H, 8.43; N, 10.64. 
(+)-(1H-Indol-5-yl)-carbamic acid (2R)-hydroxy-3-isobutylamino-propyl ester (31) 
Compound 31 was obtained as yellow thick oil (0.270 g, 92%) from 21 (0.24 g, 0.96 mmol), i-BuNH2 
(0.3 mL, 2.9 mmol), after 34 h. [α]D
20
 +4.9 (c 1.4, CH3OH); Rf 0.6 (CHCl3/CH3OH 7:3); δH (500 MHz, 
CDCl3) 8.45 (1H, s), 7.66 (1H, s), 7.27–7.04 (3H, m), 6.46 (1H, s), 4.28–4.25 (1H, m), 4.13–3.94 (2H, 
m), 2.75–2.41 (4H, m), 1.75–1.70 (1H, m), 0.91 (3H, d, J = 3.0 Hz), 0.89 (3H, d, J = 3.0 Hz); δC (125 
MHz, CDCl3) 154.4, 133.0, 130.1, 128.0, 125.3, 125.1, 115.5, 111.3, 102.6, 67.9, 67.2, 57.6, 51.3, 
28.3, 20.5. IR (cm
-1
) 3316, 2958, 1704, 1557, 1481, 1237, 1063. Anal. Calcd for C16H23N3O3: C, 
62.93; H, 7.59; N, 13.76. Found: C, 62.89; H, 7.55; N, 13.68. 
 
Synthesis of arylsulfonamides: general procedure 
Dry triethylamine (0.14 mL, 1.01 mmol) and the suitable arylsulfonyl chloride (0.93 mmol) were 
added to a stirred solution of the substrate (0.78 mmol) in dry CH2Cl2 (40 mL) at room 
temperature under argon atmosphere. After 24 h (TLC control in CHCl3/CH3OH 99:1) the reaction 
  
mixture was quenched by adding a 5% solution of H2SO4 and extracted by CH2Cl2. The organic layer 
was washed with a NaHCO3 (saturated aqueous solution) and brine, then it was dried over Na2SO4 
and concentrated under reduced pressure. The crude was purified by column chromatography on 
silica gel (CHCl3/CH3OH 99:1). 
(+)--N-[(2R)-Hydroxy-3-(1H-indol-4-yloxy)-propyl]-N-isobutyl-4-nitro-benzenesulfonamide (12a) 
Compound 12a was isolated as a yellow solid (0.285 g, 82%). Mp 142 °C; [α]D
20
 +24.0 (c 1.0, CHCl3); 
Rf 0.6 (CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.25 (1H, s), 8.18 (2H, d, J = 8.5 Hz), 7.90 (2H, d, J = 
8.5 Hz), 7.06 (1H, s), 6.98-7.01 (2H, m), ), 6.42 (1H, s), 6.39 (1H, d, J = 8.0 Hz), 4.18–4.09 (1H, m), 
3.41–3.37 (1H, m), 3.13–2.95 (5H, m), 1.98–1.94 (1H, m), 0.96-0.84 (6H, m); δC (125 MHz, CDCl3) 
151.3, 149.1, 145.8, 133.3, 128.4, 128.2, 124.5, 124.2, 119.3, 107.8, 102.6, 98.5, 74.2, 65.3, 57.7, 
52.2, 25.7, 20.9. IR (cm-1) 3408, 3123, 2898, 1489, 1353, 1224. Anal. Calcd for C21H25N3O6S: C, 
56.36; H, 5.63; N, 9.39; S, 7.17. Found: C, 56.38; H, 5.61; N, 9.35; S, 7.20. 
(+)-N-[(2R)-Hydroxy-3-(1H-indol-4-yloxy)-propyl]-N-isobutyl-3,4-dimethoxy-benzenesulfonamide 
(12b) 
Compound 12b was isolated as a white solid (0.340 g, 94%). Mp 118 °C; [α]D
20
 +4.1 (c 1.6, CHCl3); 
Rf 0.6 (CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.31 (1H, s), 7.47 (1H, dd, J = 2.0 and 8.5 Hz), 7.29 
(1H, d, J = 2.0 Hz), 7.14-7.06 (3H, m), 6.95 (1H, d, J = 8.5 Hz), 6.58-6.53 (2H, m), 4.39 (1H, bs), 4.22–
4.00 (2H, m), 3.85 (3H, s), 3.82 (3H, s), 3.29 (2H, d, J = 5.5 Hz), 3.02–2.97 (2H, m), 2.87-2.83 (1H, 
m), 1.95–1.90 (1H, m), 1.32-1.29 (2H, m), 0.87 (3H, d, J = 2.5 Hz), 0.81 (3H, d, J = 2.5 Hz); δC (125 
MHz, CDCl3) 153.0, 150.1, 148.5, 132.9, 129.1, 128.4, 124.1, 118.5, 118.2, 115.8, 112.4, 107.5, 
102.5, 99.0, 74.1, 66.7, 57.1, 56.2, 55.3, 26.5, 20.9. IR (cm
-1
) 3421, 3118, 2954, 1565, 1320, 1148. 
Anal. Calcd for C23H30N2O6S: C, 59.72; H, 6.54; N, 6.06; S, 6.93. Found: C, 59.68; H, 6.52; N, 6.11; S, 
6.90. 
(+)-N-[(2R)-Hydroxy-3-(1H-indol-5-yloxy)-propyl]-N-isobutyl-4-nitro-benzenesulfonamide (13a) 
Compound 13a was isolated as a yellow solid (0.279 g, 80%). Mp 135 °C; [α]D
20
 +18.0 (c 0.8, CHCl3); 
Rf 0.7 (CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.29 (1H, d, J = 8.5 Hz), 8.16 (1H, s), 7.99 (2H, d, J = 
8.5 Hz), 7.27 (1H, d, J = 7.0 Hz), 7.20 (1H, d, J = 2.5 Hz), 7.07 (1H, s), 6.80 (1H, dd, J = 1.5 and 8.5 
Hz), 6.47 (1H, s), 4.22–4.18 (1H, m), 4.00–3.99 (2H, m), 3.42–3.38 (2H, m), 3.09–3.05 (2H, m), 2.86 
(2H, d, J = 4.5 Hz), 2.01–1.98 (1H,m), 0.92 (3H, d, J = 2.5 Hz), 0.90 (3H, d, J = 2.5 Hz); δC (125 MHz, 
CDCl3) 152.6, 149.9, 145.1, 131.3, 128.5, 128.3, 124.0, 112.3, 111.8, 103.8, 102.4, 70.2, 68.8, 57.4, 
51.8, 26.7, 19.9. IR (cm-1) 3417, 3102, 2961, 1529, 1349, 1159. Anal. Calcd for C21H25N3O6S: C, 
56.36; H, 5.63; N, 9.39; S, 7.17. Found: C, 56.38; H, 5.61; N, 9.34; S, 7.15. 
  
(+)-N-[(2R)-Hydroxy-3-(1H-indol-5-yloxy)-propyl]-N-isobutyl-3,4-dimethoxy-benzenesulfonamide 
(13b) 
Compound 13b was isolated as a white solid (0.339 g, 94%). Mp 118 °C; [α]D
20 +4.1 (c 1.6, CHCl3); 
Rf 0.6 (CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.14 (1H, s), 7.45 (1H, dd, J  1.5 and 8.0 Hz), 7.29–
7.26 (2H, m), 7.19 (1H, d, J = 2.5 Hz), 7.09 (1H, s), 6.93 (1H, d, J = 8.5 Hz), 6.83 (1H,dd, J 2.0 and 8.5 
Hz), 6.47 (1H, t, J 1.0 Hz), 4.26–4.22 (1H, m), 4.06–3.99 (2H, m), 3.93 (3H, s), 3.91 (3H, s), 3.33–3.21 
(2H, m), 3.04–2.92 (2H,m), 1.98–1.96 (1H, m), 0.94 (3H, d, J = 8.5 Hz), 0.90 (3H, d, J 8.5 Hz); δC (125 
MHz, CDCl3) 152.8, 152.6, 149.1, 131.3, 130.5, 128.3, 125.1, 121.3, 112.4, 111.7, 110.6, 109.9, 
103.7, 102.4, 70.3, 69.2, 58.3, 56.2, 56.0, 52.7, 27.0, 20.0. IR (cm
-1
) 3390, 2954, 1509, 1262, 1137. 
Anal. Calcd for C23H30N2O6S: C, 59.72; H, 6.54; N, 6.06; S, 6.93. Found: C, 59.70; H, 6.51; N, 6.03; S, 
6.90. 
(+)-N-[(2R)-Hydroxy-3-(1H-indol-6-yloxy)-propyl]-N-isobutyl-4-nitro-benzenesulfonamide (14a) 
Compound 14a was isolated as a yellow solid (0.265 g, 76%). Mp 131 °C; [α]D
20
 +10.8 (c 0.5, CHCl3); 
Rf 0.7 (CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.35 (2H, dd, J= 2.0 and 7.0 Hz), 8.10 (1H, s), 8.03 
(2H, dd, J= 2.0 and 7.0 Hz), 7.52 (1H, d, J = 8.5 Hz), 7.15 (1H, m), 7.15 (1H, d, J= 2.0 Hz), 6.77 (1H, 
dd, J= 2.0 and 8.5 Hz), 6.51 (1H, m), 4.25 (1H, bs), 4.03 (2H, d, J= 5.0 Hz), 3.43–3.38 (2H, m), 3.09–
3.06 (2H, m), 2.88 (1H, bs), 2.03–2.00 (1H, m), 0.94 (3H, d, J = 2.5 Hz), 0.91 (3H, d, J = 2.5 Hz); δC 
(125 MHz, CDCl3) 154.8, 150.0, 144.9, 136.3, 128.5, 124.3, 123.4, 122.9, 121.5, 110.0, 102.4, 95.4, 
69.9, 68.8, 57.7, 51.9, 29.5, 19.9. IR (cm
-1
) 3430, 3156, 2889, 1565, 1332, 1104. Anal. Calcd for 
C21H25N3O6S: C, 56.36; H, 5.63; N, 9.39; S, 7.17. Found: C, 56.40; H, 5.66; N, 9.40; S, 7.20. 
(+)-N-[(2R)-Hydroxy-3-(1H-indol-6-yloxy)-propyl]-N-isobutyl-3,4-dimethoxy-benzenesulfonamide 
(14b) 
Compound 14b was isolated as a white solid (0.339 g, 94%). Mp 126 °C; [α]D
20
 +2.2 (c 1.0, CHCl3); 
Rf 0.6 (CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.23 (1H, bs), 7.51 (1H, d, J = 8.5 Hz), 7.46 (1H, dd, 
J = 2.0 and 8.5 Hz), 7.30 (1H, d, J= 2.0 Hz), 7.14-7.13 (1H, m), 6.94 (1H, d, J = 8.5 Hz), 6.83 (1H, s), 
6.76 (1H, dd, J = 2.0 and 8.5 Hz), 6.49 (1H, s), 4.25 (1H, bs), 4.03–3.96 (2H, m), 3.94 (3H, s), 3.93 
(3H, s), 3.38-3.29 (2H, m), 3.22 (1H, d, J = 4.0 Hz), 3.09–2.93 (2H, m), 2.40-1.96 (1H, m), 0.95 (3H, d, 
J = 2.5 Hz), 0.92 (3H, d, J = 2.5 Hz); δC (125 MHz, CDCl3) 155.2, 152.8, 149.3, 136.6, 130.7, 123.6, 
122.7, 121.5, 110.9, 110.5, 110.0, 102.9, 102.5, 95.5, 70.2, 69.3, 58.4, 56.6, 56.4, 52.6, 29.9, 20.3. 
IR (cm
-1
) 3402, 3098, 2922, 1560, 1280, 1142. Anal. Calcd for C23H30N2O6S: C, 59.72; H, 6.54; N, 
6.06; S, 6.93. Found: C, 59.68; H, 6.52; N, 6.10; S, 6.90. 
(+)-N-(2R,3-Dihydroxy-propyl)-N-isobutyl-4-nitro-benzenesulfonamide (18a) 
  
Compound 18a was isolated as a thick oil (0.192 g, 74%). [α]D
20 +2.8 (c 0.8, CHCl3); Rf 0.4 
(CHCl3/CH3OH 95:5); δH (500 MHz, CDCl3) 8.38 (2H, d, J= 7.5 Hz), 8.03 (2H, d, J= 7.0 Hz), 3.93-3.89 
(1H, m), 3.73-3.65 (1H, m), 3.23 (2H, d, J= 6.5 Hz), 3.04-3.00 (3H, m), 1.98-1.92 (1H, m), 0.91 (3H, d, 
J= 2.5 Hz), 0.90 (3H, d, J= 2.5 Hz); δC (125 MHz, CDCl3) 150.1, 144.6, 128.5, 124.4, 70.1, 58.2, 51.8, 
27.1, 19.9. IR (cm
-1
) 3410, 3071, 2957, 1709, 1535, 1346, 1161. Anal. Calcd for C13H20N2O6S: C, 
46.98; H, 6.07; N, 8.43; S, 9.65. Found: C, 46,95; H, 6.09; N, 8.46; S, 9.62. 
(+)-N-(2R,3-Dihydroxy-propyl)-N-isobutyl-3,4-dimethoxy-benzenesulfonamide (18b) 
Compound 18b was isolated as a thick oil (0.211 g, 78%). [α]D
20 +1.5 (c 1.5, CHCl3); Rf 0.3 
(CHCl3/CH3OH 97:3); δH (500 MHz, CDCl3) 7.44 (1H, d, J = 8.5 Hz), 7.23 (1H, s), 6.96 (1H, d, J = 8.5 
Hz), 3.93 (3H, s), 3.91 (3H, s), 3.70-3.51 (3H, m), 2.73-2.58 (2H, m), 2.40-2.31 (2H, m), 1.96-1.89 
(1H, m), 0.90 (3H, d, J = 2.5 Hz), 0.89 (3H, d, J = 2.5 Hz); δC (125 MHz, CDCl3) 153.0, 150.1, 129.2, 
118.4, 115.6, 112.2, 68.0, 64.9, 57.3, 56.2, 51.8, 25.3, 20.2. IR (cm-1) 3391, 3172, 2808, 1523, 1354, 
1187. Anal. Calcd for C15H25NO6S: C, 51.86; H, 7.25; N, 4.03; S, 9.23. Found: C, 51.84; H, 7.22; N, 
4.06; S, 9.22. 
(+)-(1H-indol-4-yl)-carbamic acid (2R)-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl 
ester (32a) 
Compound 32a was isolated as a yellow thick oil (0.332 g, 87%). [α]D
20 +10.2 (c 1.2, CHCl3); Rf 0.6 
(CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.36 (bs, 1H), 8.16 (2H, d, J = 8.5 Hz), 7.87 (2H, d, J = 8.5 
Hz), 7.18-7.20 (m, 4H), 6.96 (bs, 1H), 6.50-6.51 (m, 1H), 4.26 (1H, dd, J = 5.0 and 11.5 Hz), 4.16–
4.08 (2H, m), 3.25–3.02 (4H, m), 1.95–1.90 (1H, m), 0.91 (3H, d, J = 3.0 Hz), 0.89 (3H, d, J = 3.0 Hz); 
δC (125 MHz, CDCl3) 153.7, 151.2, 145.9, 136.1, 130.3, 128.4, 127.3, 124.4, 124.1, 114.9, 112.5, 
102.6, 66.3, 64.5, 57.3, 52.2, 25.8, 19.9. IR (cm
-1
) 3420, 3073, 2952, 1721, 1513, 1354, 1168. Anal. 
Calcd for C22H26N4O7S: C, 53.87; H, 5.34; N, 11.42; S, 6.54. Found: C, 53.83; H, 5.38; N, 11.46; S, 
6.52. 
(+)-(1H-indol-4-yl)-carbamic acid (2R)-hydroxy-3-[isobutyl-(3,4-dimethoxy-benzenesulfonyl)-
amino]-propyl ester (32b) 
Compound 32b was isolated as a thick oil (0.335 g, 85%). [α]D
20
 +2.4 (c 1.0, CHCl3); Rf 0.7 
(CH2Cl2/EtOAc 98:2); δH (500 MHz, CDCl3) 8.36 (1H, bs), 7.47 (1H, m), 7.33 (1H, d, J = 8.5 Hz), 7.18 
(1H, d, J= 5.5 Hz), 7.10-7.06 (3H, m), 6.9 (1H, m), 6.80 (1H, d, J = 8.5 Hz), 6.4 (1H, s), 4.26-4.17 (2H, 
m), 4.08 (1H, bs), 3.82 (3H, s), 3.79 (3H, s), 3.41 (1H, bs), 3.18-3.05 (2H, m), 2.93-2.80 (2H, m), 1.85-
1.78 (1H, m), 0.85 (3H, d, J = 2.5 Hz), 0.82 (3H, d, J = 2.5 Hz); δC (125 MHz, CDCl3) 152.7, 149.1, 
136.5, 130.0, 129.5, 123.9, 122.6, 121.3, 110.6, 109.9, 107.8, 98.4, 69.2, 66.9, 58.4, 56.2, 56.1, 
  
52.5, 27.1, 20.1, 19.9. IR (cm
-1
) 3392, 3106, 2955, 1548, 1193, 1178. Anal. Calcd for C24H31N3O7S: C, 
57.01; H, 6.18; N, 8.31; S, 6.34. Found: C, 57.04; H, 6.15; N, 8.33; S, 6.37. 
(+)-(1H-indol-5-yl)-carbamic acid (2R)-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl 
ester (33a) 
Compound 33a was isolated as a yellow thick oil (0.344 g, 90%). [α]D
20 +8.8 (c 0.8, CHCl3); Rf 0.6 
(CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.38 (1H, s), 8.24 (2H, br s), 7.95 (2H, br s), 7.63 (1H, s), 
7.28–7.00 (4H, m), 6.46 (1H, s), 4.27 (1H, dd, J = 5.0 and 11.5 Hz), 4.18–4.09 (2H, m), 3.27–3.01 
(4H, m), 1.95–1.91 (1H, m), 0.92 (3H, d, J = 3.0 Hz), 0.89 (3H, d, J = 3.0 Hz); δC (125 MHz, CDCl3) 
154.2, 149.9, 144.8, 133.1, 129.8, 128.6, 128.4, 128.1, 125.5, 124.3, 115.6, 111.5, 102.4, 68.8, 66.8, 
57.4, 51.6, 26.8, 19.9. IR (cm
-1
) 3410, 3071, 2957, 1709, 1535, 1346, 1161. Anal. Calcd for 
C22H26N4O7S: C, 53.87; H, 5.34; N, 11.42; S, 6.54. Found: C, 53.82; H, 5.36; N, 11.45; S, 6.51. 
(+)-(1H-indol-5-yl)-carbamic acid (2R)-hydroxy-3-[isobutyl-(3,4-dimethoxy-benzenesulfonyl)-
amino]-propyl ester (33b) 
Compound 33b was isolated as a thick oil (0.323 g, 82%). [α]D
20 +1.8 (c 1.0, CHCl3); Rf 0.7 
(CH2Cl2/EtOAc 98:2); δH (500 MHz, CDCl3) 8.38 (1H, bs), 7.72-7.68 (1H, m), 7.43-7.39 (1H, m), 7.32- 
7.24 (2H, m), 7.19 (1H, s), 7.11-7.07 (1H, m), 6.95-6.85 (1H, m), 6.44 (1H, s), 4.28-4.14 (2H, m), 4.07 
(1H, bs), 3.84 (3H, s), 3.83 (3H, s), 3.58 (1H, bs), 3.25-3.12 (2H, m), 3.03-2.85 (2H, m), 1.91-1.82 
(1H, m), 0.88 (3H, d, J = 2.5 Hz), 0.83 (3H, d, J = 2.5 Hz); δC (125 MHz, CDCl3) 154.3, 152.7, 149.1, 
133.0, 130.1, 129.9, 128.0, 125.3, 121.3, 115.6, 111.6, 111.3, 110.6, 109.9, 102.6, 69.2, 66.8, 58.3, 
56.2, 56.1, 52.5, 27.1, 20.1, 19.9. IR (cm-1) 3445, 3108, 2918, 1498, 1265, 1123. Anal. Calcd for 
C24H31N3O7S: C, 57.01; H, 6.18; N, 8.31; S, 6.34. Found: C, 57.04; H, 6.22; N, 8.28; S, 6.32. 
(+)-(1H-indol-5-yl)-carbamic acid (2R)-hydroxy-3-[isobutyl-(4-methoxy-benzenesulfonyl)-amino]-
propyl ester (33c) 
Compound 33c was isolated as a brown solid (0.285 g, 77%). Mp 96 °C; [α]D
20
 +3.2 (c 1.0, CHCl3); Rf 
0.6 (CHCl3/MeOH 95:5); δH (500 MHz, CDCl3) 8.44 (1H, s), 7.69-7.50 (3H, m), 7.23 (1H, d, J = 9.5 Hz), 
7.13 (1H, s), 7.04 (1H, d, J = 9.0 Hz), 6.96-6.88 (3H, m), 6.42 (1H, s), 4.24-4.09 (3H, m), 3.77 (3H, s), 
3.60 (1H, s), 3.46 (1H, d, J = 8.5 Hz), 3.13 (2H, bs), 2.91 (2H, d, J = 8.5 Hz), 1.24-1.17 (6H, m); δC (125 
MHz, CDCl3) 162.9, 154.4, 133.0, 130.9, 129.9, 129.5, 128.7, 128.0, 125.3, 115.6, 114.3, 111.3, 
102.4, 69.1, 66.7, 58.3, 55.5, 52.4, 27.1, 19.9. IR (cm-1) 3486, 3122, 2866, 1423, 1196, 1141. Anal. 
Calcd for C23H29N3O6S: C, 58.09; H, 6.15; N, 8.84; S, 6.74. Found: C, 58.11; H, 6.18; N, 8.82; S, 6.75. 
 
(+)-(R)-4-Amino-N-[3-(1H-indol-5-yloxy)-2-hydroxypropyl]-N-isobutyl-benzenesulfonamide (13c) 
  
Compound 13a (0.104 g, 0.23 mmol) was added to a suspension of 10% Pd/C (14 mg) in ethyl 
acetate (20 mL) under hydrogen atmosphere. After 28 h the reaction mixture was filtered on a 
plate of Celite, concentrated under vacuo and purified by column chromatography on silica gel 
(CHCl3/CH3OH 95:5) to afford compound 13c as a violet thick oil (0.071 g, 74%). [α]D
20
 +12.0 (c 1, 
CH3OH); Rf 0.3 (CHCl3/CH3OH 95:5); δH (500 MHz, CD3OD) 7.64 (2H, d, J = 9.0 Hz), 7.26 (1H, d, J = 
8.5 Hz), 7.18 (1H, d, J = 3.0 Hz), 7.06 (1H, d, J = 2.5 Hz), 6.99 (1H, d, J = 9.0 Hz), 6.79 (1H, dd, J = 2.0 
and 9.0 Hz), 6.36 (1H, d, J = 2.5 Hz), 4.18–4.14 (1H, m), 4.00 (1H, dd, J = 4.0 and 10.0 Hz), 3.94 (1H, 
dd, J  = 5.0 and 9.5 Hz), 3.42 (1H, dd, J = 4.5 and 15.0 Hz), 3.11 (1H, dd, J 7.0 and 14.5 Hz), 2.96 (1H, 
dd, J 7.5 and 13.5 Hz), 2.88 (1H, dd, J = 7.5 and 13.5 Hz), 2.01–1.97 (1H, m), 0.93 (3H, d, = 3.0 Hz), 
0.91 (3H, d, J 3.0 Hz); δC (125 MHz, CD3OD) 157.1, 154.1, 133.1, 129.8, 126.2, 114.5, 113.2, 112.9, 
112.7, 104.4, 102.2, 71.9, 70.3, 59.1, 53.1, 28.0, 20.5. IR (cm-1) 3465, 3312, 3065, 2954, 1509, 
1262, 1137. Anal. Calcd for C21H27N3O4S: C, 60.41; H, 6.52; N, 10.06; S, 7.68. Found: C, 60.39; H, 
6.53; N, 10.10; S, 7.65. 
Toluene-4-sulfonic acid (2R)-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl ester  
and Toluene-4-sulfonic acid (2R)-hydroxy-3-[isobutyl-(3,4-dimethoxy-benzenesulfonyl)-amino]-
propyl ester 
Dry pyridine (0.095 mL, 1.16 mmol) and tosyl chloride (0.222 g, 1.16 mmol) were added to a 
stirred solution of compound 18a (0.351 g, 1.06 mmol) (or 18b, 0.368 g, 1.06 mmol) in dry CH2Cl2 
(15 mL) at room temperature. The mixture was stirred in argon atmosphere for 20 h, then it was 
washed with diluted hydrochloric acid (0.1 M, 10 mL), with a saturated aqueous solution of 
NaHCO3 and finally with brine. The organic layer was dried and evaporated under reduced 
pressure. Toluene-4-sulfonic acid (2R)-hydroxy-3-[isobutyl-(4-nitro-benzenesulfonyl)-amino]-propyl 
ester and Toluene-4-sulfonic acid (2R)-hydroxy-3-[isobutyl-(3,4-dimethoxy-benzenesulfonyl)-
amino]-propyl ester were obtained as yellow oil and used in the subsequent reaction without  any 
purification. 
N-Isobutyl-4-nitro-N-(R)-oxiranylmethyl-benzenesulfonamide (19a) and N-Isobutyl-3,4-dimethoxy-
N-(R)-oxiranylmethyl-benzenesulfonamide (19b) 
Potassium carbonate was added to a stirred solution of the crude tosyl derivative of 18a (or 18b) 
in methanol (26 mL) at room temperature. 
After disappearance of the starting material, the reaction was quenched by adding ammonium 
chloride (saturated aqueous solution), then extracted with diethyl ether and washed with brine. 
  
The combined extracts were dried over Na2SO4 and evaporated under reduced pressure to give 
the crude epoxide. 
N-Isobutyl-4-nitro-N-(R)-oxiranylmethyl-benzenesulfonamide (19a) was isolated as thick oil (0.280 
g, 84% in two steps) [α]D
20
 +2.4 (c 1.2, CHCl3); Rf 0.6 (EP/EtOAc 7:3); δH (500 MHz, CDCl3) 8.38 (2H, 
d, J = 8.5 Hz), 8.04 (2H, d, J = 8.5 Hz), 3.70 (1H, dd, J= 15.0 and 3.0 Hz), 3.13 (1H, dd, J= 14.0 and 8.0 
Hz), 3.06-2.90 (3H, m), 2.79-2.81 (1H, dd, J= 5.0 and 3.0 Hz), 2.53 (1H, dd, J= 5.0 and 3.0 Hz), 2.06-
1.97 (1 H, m), 0.97 (3H, d, J = 7.0 Hz), 0.92 (3H, d, J = 6.5 Hz); δC (125 MHz, CDCl3) 151.3, 145.9, 
128.4, 124.3, 58.1, 51.6, 50.2, 45.4, 25.7, 20.2. IR (cm
-1
) 3389, 3135, 2885, 1537, 1328, 1137. Anal. 
Calcd for C13H18N2O5S: C, 49.67; H, 5.77; N, 8.91; S, 10.20. Found: C, 49.64; H, 5.79; N, 8.88; S, 
10.23. 
N-Isobutyl-3,4-dimethoxy-N-(R)-oxiranylmethyl-benzenesulfonamide (19b) was isolated as thick oil 
(0.282 g, 81% in two steps) [α]D
20
 +1.6 (c 0.8, CHCl3); Rf 0.7 (EP/EtOAc 6:4); δH (500 MHz, CDCl3) 
7.42 (1H, d, J = 8.5 Hz), 7.25 (1H, s), 6.95 (1H, d, J = 8.5 Hz), 4.05-3.97 (1H, m), 3.95 (3H, s), 3.93 
(3H, s), 3.56-3.50 (3H, m), 3.20-2-97 (3H, m), 1.98-1.92 (1H, m), 0.97-0.89 (6H, m); δC (125 MHz, 
CDCl3) 153.2, 150.3, 129.1, 118.5, 115.4, 112.2, 56.6, 56.1, 51.7, 50.2, 45.6, 25.7, 20.1. IR (cm
-1
) 
3492, 3202, 2796, 1540, 1365, 1204. Anal. Calcd for C15H23NO5S: C, 54.69; H, 7.04; N, 7.25; S, 9.73. 
 
Ring opening of epoxides with aminoindoles: general procedure 
4-Aminoindole 20 (or 5-aminoindole 21) (0.145 g, 1.10 mmol) was added to a stirred solution of 
the epoxide 19a (0.283 g, 0.9 mmol) (or epoxide 19b, 0.296 g, 0.9 mmol) in i-PrOH (15 mL). The 
mixture was heated at reflux temperature until disappearance of epoxide (about 10 h, TLC control, 
CHCl3/CH3OH 9:1). After cooling, the solvent was removed under reduced pressure and the crude 
was purified by column chromatography on silica gel (eluent: CHCl3/CH3OH 9:1). 
N-[(2R)-Hydroxy-3-(1H-indol-4-ylamino)-propyl]-N-isobutyl-4-nitro-benzenesulfonamide (22a) was 
isolated as a brown thick oil (0.309 g, 77%). [α]D
20
 +18.0 (c 0.8, CHCl3); Rf 0.6 (CHCl3/CH3OH 99:1); 
δH (500 MHz, CDCl3) 8.18 (2H, d, J = 8.5 Hz), 8.15 (1H, s), 7.85 (2H, d, J = 8.5 Hz), 7.06 (1H, s), 6.98-
6.93 (1H, m), 6.80 (1H, d, J = 8.0 Hz), 6.42 (1H, s), 6.19 (1H, d, J = 7.5 Hz), 4.15–4.04 (1H, m), 3.39–
3.35 (1H, m), 3.24–3.19 (3H, m), 2.96 (2H, d, J = 7.5 Hz), 1.91–1.84 (1H, m), 0.85-0.82 (6H, m); δC 
(125 MHz, CDCl3) 151.5, 146.1, 135.8, 135.3, 128.3, 127.4, 124.3, 124.2, 107.2, 104.3, 102.1, 99.4, 
68.2, 57.3, 53.2, 51.2, 25.9, 20.1. IR (cm
-1
) 3422, 3112, 2945, 1587, 1298, 1087. Anal. Calcd for 
C21H26N4O5S: C, 56.49; H, 5.87; N, 12.55; S, 7.18. Found: C, 56.51; H, 5.88; N, 12.52; S, 7.20. 
  
N-[(2R)-Hydroxy-3-(1H-indol-4-ylamino)-propyl]-N-isobutyl-3,4-dimethoxy-benzenesulfonamide 
(22b) was isolated as a brown thick oil (0.278 g, 67%). [α]D
20
 +3.5 (c 1.2, CHCl3); Rf 0.5 
(CHCl3/CH3OH 99:1); δH (500 MHz, CDCl3) 8.18 (1H, s), 7.35 (1H, dd, J = 2.0 and 8.5 Hz), 7.02-6.94 
(2H, m), 7.83-7.78 (2H, m), 6.47-6.40 (1H, m), 6.24 (1H, d, J = 8.5 Hz), 4.18 (1H, bs), 3.85 (3H, s), 
3.80 (3H, s), 3.40–3.36 (1H, m), 3.29-3.18 (2H, m), 3.15–2.82 (4H, m), 1.90-1.81 (1H, m), 0.87 (3H, 
d, J = 2.5 Hz), 0.81 (3H, d, J = 2.5 Hz); δC (125 MHz, CDCl3) 152.7, 149.2, 141.3, 136.5, 130.2, 123.4, 
122.1, 121.3, 117.2, 110.7, 110.0, 101.9, 99.8, 98.8, 69.3, 58.6, 56.3, 56.2, 54.0, 47.4, 27.3, 20.1, 
20.0. IR (cm
-1
) 3408, 3145, 2814, 1505, 1290, 1121. Anal. Calcd for C23H31N3O5S: C, 59.85; H, 6.77; 
N, 9.10; S, 6.95. Found: C, 59.88; H, 6.80; N, 9.07; S, 6.99. 
N-[(2R)-Hydroxy-3-(1H-indol-5-ylamino)-propyl]-N-isobutyl-4-nitro-benzenesulfonamide (23a) was 
isolated as a brown thick oil (0.297 g, 74%). [α]D
20
 +21.0 (c 1.0, CHCl3); Rf 0.6 (CHCl3/CH3OH 99:1); 
δH (500 MHz, CDCl3) 8.18 (2H, d, J = 8.5 Hz), 8.16 (1H, s), 7.85 (2H, d, J = 8.5 Hz), 7.06 (1H, s), 6.98-
6.93 (1H, m), 6.80 (1H, d, J = 8.0 Hz), 6.42 (1H, s), 4.19 (1H, d, J = 7.5 Hz), 4.12–4.05 (1H, m), 3.41–
3.38 (1H, m), 3.25–3.21 (3H, m), 2.95 (2H, d, J = 7.5 Hz), 1.91–1.82 (1H, m), 0.85-0.82 (6H, m); δC 
(125 MHz, CDCl3) 151.5, 146.2, 137.1, 129.3, 128.3, 124.5, 124.2, 123.8, 113.6, 104.8, 102.5, 101.7, 
68.4, 57.1, 53.7, 51.4, 26.2, 20.1. IR (cm-1) 3465, 3112, 2944, 1517, 1323, 1178. Anal. Calcd for 
C21H25N4O5S: C, 56.49; H, 5.87; N, 12.55; S, 7.18. Found: C, 56.51; H, 5.89; N, 12.51; S, 7.15. 
N-[(2R)-Hydroxy-3-(1H-indol-5-ylamino)-propyl]-N-isobutyl-3,4-dimethoxy-benzenesulfonamide 
(23b) was isolated as a brown thick oil (0.286 g, 69%). [α]D
20 +4.1 (c 1.0, CHCl3); Rf 0.6 
(CHCl3/CH3OH 98:2); δH (500 MHz, CDCl3) 8.06 (1H, s), 7.42 (1H, dd, J = 2.0 and 8.5 Hz), 7.22-7.14 
(2H, m), 6.95-6.91 (2H, m), 6.71 (1H, d, J = 8.5 Hz), 6.41 (1H, s), 4.15-4.13 (1H, m), 3.94 (3H, s), 3.91 
(3H, s), 3.36–3.16 (4H, m), 3.02-2.91 (2H, m), 1.94-1.89 (1H, m), 0.94 (3H, d, J = 2.5 Hz), 0.92 (3H, d, 
J = 2.5 Hz); δC (125 MHz, CDCl3) 152.9, 149.4, 141.4, 131.1, 130.5, 129.0, 125.0, 121.6, 113.2, 112.0, 
110.9, 110.2, 104.3, 102.2, 69.2, 58.7, 56.5, 56.4, 54.1, 50.1, 27.5, 20.4, 20.2. IR (cm
-1
) 3422, 3202, 
2774, 1445, 1288, 1091. Anal. Calcd for C23H31N3O5S: C, 59.85; H, 6.77; N, 9.10; S, 6.95. Found: C, 
59.84; H, 6.79; N, 9.09; S, 6.94. 
(1H-Indol-4-yl)-carbamic acid 4-nitro-phenyl ester (24) and (1H-Indol-5-yl)-carbamic acid 4-nitro-
phenyl ester (25). 
Dry triethylamine (0.54 mL, 3.9 mmol) and p-nitrophenylchlorocarbonate (0.786 g, 3.9 mmol) 
were added to a stirred solution of 4-aminoindole 22 (or 5-aminoindole 23) (0.396 g, 3.0 mmol) in 
dry CH2Cl2 (30 mL) at room temperature and in argon atmosphere. After 2 h a TLC control 
(CH2Cl2/EtOAc 99:1) showed the disappearance of the aminoindole and the reaction was 
  
quenched by adding water (15 mL). The organic layer was washed with brine, dried over Na2SO4 
and concentrated in vacuo affording compound 24 (or 25) as a yellow solid. This compound was 
used as crude for the following reaction. 
(+)-(1H-Indol-4-yl)-carbamic acid (R)-oxiranylmethyl ester (26) and (+)-(1H-Indol-5-yl)-carbamic 
acid (R)-oxiranylmethyl ester (27) 
Dry triethylamine (0.7 mL, 5 mmol) and S-glycidol 1 (0.279 g, 3.8 mmol) were added to a stirred 
solution of the crude compound 24 (or 25) in dry CH2Cl2 (30 mL) at room temperature and under 
argon atmosphere. After 10 h and the disappearance of glycidol (by TLC monitoring, CH2Cl2/EtOAc 
8:2) the mixture was diluted with CH2Cl2. The organic layer was washed with brine, dried over 
Na2SO4 and concentrated in vacuo. The crude was purified by column chromatography 
(CH2Cl2/EtOAc 8:2). 
(+)-(1H-Indol-4-yl)-carbamic acid (R)-oxiranylmethyl ester (26) was obtained as a yellow solid 
(0.612 g, 88% in two steps). Mp 113 °C; [α]D
20 +9.2 (c 1.2, CHCl3); Rf 0.4 (CH2Cl2/EtOAc 8:2); δH (500 
MHz, CDCl3) 8.36 (1H, bs,) 7.18-7.20 (4H, m), 6.96 (1H, bs), 6.50-6.51 (1H, m), 4.60-4.63 (1H, m), 
4.03-4.10 (1H, m), 3.32-3.45 (1H, m), 2.90-2.92 (1H, m), 2.71-2.75 (1H, m); δC (125 MHz, CDCl3) 
153.8, 134.7, 130.3, 127.8, 124.5, 114.9, 112.4, 106.9, 102.6, 64.6, 50.3, 44.2. IR (cm
-1
) 3465, 3218, 
2804, 1425, 1308, 1121. Anal. Calcd for C12H12N2O3: C, 62.06; H, 5.21; N, 12.06. Found: C, 62.09; H, 
5.24; N, 12.08. 
(+)-(1H-Indol-5-yl)-carbamic acid (R)-oxiranylmethyl ester (27) was obtained as a yellow solid 
(0.626 g, 90% in two steps). Mp 109 °C; [α]D
20
 +7.0 (c 1, CHCl3); Rf 0.3 (CH2Cl2/EtOAc 8:2); δH (500 
MHz, CDCl3) 8.18 (1H s), 7.69 (1H, s), 7.33–7.13 (3H, m), 6.70 (1H, s), 6.51 (1H, d, J = 2.5 Hz), 4.56 
(1H, dd, J = 3.0 and 12.5 Hz), 4.01 (1H, dd, J = 5.5 and 11.0 Hz), 3.30–2.71 (3H, m); δC (125 MHz, 
CDCl3) 153.7, 133.0, 130.0, 128.1, 125.3, 115.7, 111.3, 111.1, 102.7, 65.5, 49.8, 44.7. IR (cm
-1
) 
3456, 3264, 2708, 1418, 1292, 1065. Anal. Calcd for C12H12N2O3: C, 62.06; H, 5.21; N, 12.06. Found: 
C, 62.09; H, 5.24; N, 12.09. 
 
Protease inhibition assay 
Biological assays were performed by measuring the increase in the fluorescence due to the Abz-
NF*-6 (Km=37±8 µM; Vmax=690±90 nmol min
-1
 (mg protease)
-1
; Kcat=0.29±0.03 S
-1
; Kcat/Km=7.8±0.3 
mM-1) substrate’s hydrolysis by a commercially available HIV-PR, at a λexc and at a λem of 325 nm 
and 420 nm, respectively; 114 µL of the fluorogenic substrate (with a concentration of 53 µM, 
obtained by diluting 10 µL of a stock solution containing 10 mg mL-1 of substrate in DMSO with 
  
1.99 mL of pH 5.5 MES buffer) were put in a thermostated cuvette (25 °C) with 75 µL of MES buffer 
(containing 100 mM 2-[N-morpholino]ethansulfonic acid (MES)/NaOH, pH 5.5; 400 mM NaCl; 1 
mM ethylendiaminotetracetic acid (EDTA); 1 mM dithiotreitol (DTT)), obtaining a final 
concentration of 30 µM and starting measuring the fluorescence. After 1.5 min the HIV-PR was 
added (11 µL of a solution obtained diluting 1:100, with a MES/BSA buffer, a stock solution of 0.4 
mg mL
-1
 of HIV-PR in a 10 mM sodium phosphate pH=6.5, 1 mM EDTA/10% glycerol/0.05% 
mercaptoethanol/50–100 mM NaCl), obtaining an enzymatic concentration of 10 nm. The increase 
in the fluorescence was then measured; after 1 min the inhibitor containing solution was added (2 
µL) and the fluorescence measured for other additional 10 min. For each inhibitor, a stock solution 
in DMSO was prepared by weight, then diluted it with DMSO or MES buffer. The amount of the 
inhibition was evaluated comparing the initial rates, extrapolated from the linear parts of the 
curves obtained by plotting fluorescence versus time, of the catalyzed reaction in the presence of 
different inhibitor’s concentration. IC50 values were obtained simply by plotting the different 
slopes versus inhibitor’s concentrations (expressed using a logarithmical scale) and interpolating 
the value corresponding to the 50% of inhibition. 
 
Molecular modelling 
To inspect the binding mode of the synthesized inhibitors to the HIV-PR, conformation searching, 
docking and binding pose refining were carried out for each of the molecules using MOE program 
(Chemical Computing Group, Montreal, QC, Canada. Version 2012.10). First, crystal structures of 
Darunavir (ligand 017 from the Protein Data Bank entry 2IEO) and Nelfinavir (ligand 1UN from the 
PDB entry 2Q63) were taken as references for the sulfonamide derivatives and decahydro-
isoquinoline derivatives, respectively. Then, possible conformations of the ligands were generated 
by a grid searching algorithm considering the linkers to be the flexible part of the molecules. After 
molecular mechanics geometry optimization, each of the conformers were inserted into the 
binding site by superimposing the ligand to the reference inhibitor structure. A multi-step in situ 
energy minimization was carefully performed and the complexes were refined with help of the 
MOE LigX module. For each compound, over 30 reasonable ligand poses (out of many generated 
ligand conformations) were further refined and only the pose with the lowest energy of the 
enzyme-inhibitor complex was kept. 
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